Compounded GLP-1 vs FDA-approved GLP-1

Compounding is the preparation of a medication by combining, mixing or altering ingredients. It can meet a legitimate patient need when an FDA-approved drug is not medically appropriate—for example, because a patient needs a different formulation—or when an approved drug is not commercially available. Depending on the setting, compounding may be performed by a licensed pharmacist, physician or FDA-registered outsourcing facility under specific federal conditions. FDA explains the compounding framework here.

A compounded drug is not an FDA-approved generic. FDA does not review the finished compounded product for safety, effectiveness or quality before it is marketed. Oversight also differs: state boards generally supervise traditional state-licensed pharmacies, while FDA-registered outsourcing facilities face federal inspection and current good manufacturing practice requirements. Registration still does not mean FDA approved the facility’s individual products. FDA describes these distinctions and risks.

Shortages helped expand access because federal law allows certain shortage-related compounding under defined conditions. That flexibility was not a permanent authorization to mass-produce inexpensive copies of available brand drugs.

FDA determined that the national tirzepatide injection shortage was resolved in December 2024 and the semaglutide injection shortage was resolved in February 2025. FDA’s transition periods tied to those shortages have ended: for tirzepatide, the relevant enforcement-discretion periods ended in March 2025; for semaglutide, they ended for traditional compounders in April 2025 and for outsourcing facilities in May 2025. FDA maintains the dates and legal context on its GLP-1 supply page.

As of July 2026, FDA states that semaglutide and tirzepatide are not on its drug-shortage list. This does not outlaw every individualized prescription. Under section 503A, a prescriber may document that a change in a compounded product produces a significant difference for an identified patient. It does mean that an offer built around routine copies for large numbers of customers should not be justified simply by referring to the old shortage.

FDA has also warned telehealth companies against describing compounded GLP-1 products as the same as, generic versions of or clinically proven equivalents to approved products. The agency’s consumer page lists those marketing concerns.

The central difference is regulatory evidence about the product you receive. An FDA-approved medication has undergone premarket review of its safety, effectiveness, quality, manufacturing and labeling. A compounded product has not undergone that finished-product review. Poor compounding can produce contamination or too much or too little active ingredient, although that does not establish that every compounded prescription is defective. FDA explains why it considers compounded drugs higher risk.

Delivery formats create another difference. FDA-approved injectable semaglutide products use standardized concentrations and prefilled pens. Compounded semaglutide may arrive in multidose vials, prefilled syringes or varying concentrations, with instructions expressed in milligrams, milliliters or “units.” FDA received reports of patients administering five to 20 times the intended amount and of clinicians making conversion errors; some patients required medical care or hospitalization. FDA details the reported dosing errors.

The ingredient name matters too. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base used in approved drugs, and the agency says it knows of no lawful basis for using those salt forms in compounding. FDA has also received reports involving compounded semaglutide and tirzepatide prescribed outside approved-label dosing schedules. Those reports identify safety signals, not proof that the compounded product caused every event. FDA provides the current cautions and reporting limitations.

Do not accept “partner pharmacy” as an answer. Ask for the legal name and physical address of the pharmacy that will actually dispense the medication, then check its license with your state board of pharmacy. FDA says a safer online pharmacy requires a prescription, provides a US address and telephone number and makes a licensed pharmacist available for questions. FDA provides a state-license lookup starting point.

Get the remaining answers in writing. If the company will not provide them before payment, you cannot verify the offer’s basic product and care terms.

Compare the telehealth offer with insurance coverage, pharmacy pricing and manufacturer-direct programs. Use the full recurring cost—not an introductory fee that excludes clinical visits, supplies, shipping or later months. Approved brand medication may cost less than expected when a current self-pay or savings program applies.

As of July 2026, LillyDirect lists Zepbound self-pay prices starting at $299 per month for its 2.5 mg KwikPen or vial and $399 for 5 mg. Eligible 7.5 mg through 15 mg fills are listed at $449 when refilled within 45 days; regular prices can be higher if program conditions are not met. Lilly publishes the current prices and restrictions.

As of July 2026, NovoCare lists an introductory Wegovy injection offer of $199 per month for two monthly fills for eligible new patients, followed by $349 per month; eligibility, deadlines and product-specific terms apply. NovoCare displays current offer details. These are dated snapshots, not guaranteed future prices. Manufacturer programs may be changed or canceled, so recheck the official terms on the day you compare offers.

Start with the product question. If an approved option is available, clinically appropriate and affordable, it offers the clearer regulatory record because FDA has reviewed the finished product. FDA says compounded drugs should generally be reserved for patients whose needs cannot be met by an available approved drug. That is the agency’s stated position.

If a clinician identifies a patient-specific reason for compounding, evaluate the pharmacy, ingredient, container, instructions and follow-up rather than relying on the telehealth brand’s reputation. A vague claim that the formula is “personalized,” includes a vitamin or comes from an “FDA-approved pharmacy” does not establish FDA approval or legal eligibility. FDA specifically warns that it does not approve or license compounding facilities and has challenged misleading sameness and sourcing claims. FDA explains those advertising limits.

Finally, compare continuity: what happens if the price changes, the pharmacy changes, the shipment arrives warm or your prescriber decides the product should change? GLP-1 medication use requires an accurate health and medication history and ongoing access to a clinician; MedlinePlus directs patients using semaglutide to keep clinician appointments and discuss other medicines and relevant conditions. Review the federal patient information. Make medication and health decisions with a licensed clinician who knows your medical history.

FDA-approved medicines such as Wegovy and Zepbound have approved prescribing information, manufacturing controls and label language that clinicians can reference. A compounded GLP-1 product is made by a compounding pharmacy for a specific context and is not FDA-approved as a finished product. That distinction matters even when the active ingredient name sounds familiar.

FDA has warned about unapproved GLP-1 drugs used for weight loss, fraudulent compounded semaglutide and tirzepatide labels, dosing errors and misleading marketing. In 2026, FDA also reminded compounders and telehealth companies that compounded drugs must meet legal conditions and that promotional claims cannot falsely imply safety, effectiveness or equivalence to approved products.

A practical comparison should list brand name, active ingredient, dosage form, pharmacy, prescriber, lab policy, follow-up plan, refund terms and total monthly cost. A lower advertised price is not enough if the formulation, dose instructions or pharmacy source are unclear. For FDA-approved medications, compare the official label and manufacturer information; for compounded products, require a more detailed source and dosing explanation.